VistaGen Therapeutics, Inc. Form 8-K October 26, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

## CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 26, 2017

VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter)

NEVADA	001-37761	20-5093315
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

343 Allerton Ave.South San Francisco, California 94090 (Address of principal executive offices)

(650) 577-3600 (Registrant's telephone number, including area code)

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) Item 8.01 Other Events.

VistaGen Therapeutics, Inc. (the "Company") today announced that the U.S. Food and Drug Administration has authorized the Company to proceed, under its Investigational New Drug application, with its planned Phase 2 clinical study of AV-101 as a new generation oral treatment for major depressive disorder. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.

Item 9.01 Exhibits.

See Exhibit Index.

## Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VistaGen Therapeutics, Inc.

Date: October 26, 2017 By: /s/ Shawn K. Singh Shawn K. Singh Chief Executive Officer

## EXHIBIT INDEX

## Exhibit Number Description

<u>99.1</u> Press release issued by VistaGen Therapeutics Inc., dated October 26, 2017.